Compare Dropbox Inc (DBX) vs 10X Genomics Inc (TXG) Price & Performance

DBX trades at $34.59, down 0.63% today, with a bullish technical signal from moving averages and recent earnings beats. Revenue remains steady at $2.52B for 2025, with a net income margin of 20.16%. The company raised its 2026 outlook after Q2 results, supported by core file-sync-and-share growth and AI expansion. Cash flow from operations improved to $952M in 2025, though net cash flow was negative due to financing activities.

The outlook is mixed; strong profitability and bullish analyst coverage contrast with high debt levels and negative shareholder equity. Risks include competitive pressures and reliance on sustained user growth. With 37.5% of analysts rating it a buy, the stock offers growth potential but requires monitoring of balance sheet health and execution risks.

TXG trades at $58.57, up 12.57% in 24 hours, reflecting strong momentum. The stock is technically bullish with moving averages supporting the uptrend, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and revenue growth, yet remains unprofitable with a negative net income margin. Recent news highlights collaborations and acquisitions expanding its genomic capabilities.

Outlook is mixed; analyst consensus is neutral with a $46 price target below current levels, indicating caution despite recent beats. Key risks include sustained losses and competitive pressures, but operational cash flow growth and strategic expansions offer potential upside for patient investors focused on long-term biotech innovation.